Key terms

About NGM

NGM Biopharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel biologic drug candidates. Its programs include NGM707 and pembrolizumab for treating metastatic solid tumors, Aldafermin for primary sclerosing cholangitis, and NGM120 for hyperemesis gravidarum. The company was founded by Jin Long Chen on December 20, 2007 and is headquartered in South San Francisco, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest NGM news

Apr 05 10:22am ET NGM Biopharmaceuticals’ Strategic Merger and Corporate Transformation by TipRanks Mar 13 2:00am ET Ngm Biopharmaceuticals Merger at Risk: Legal Hurdles Could Jeopardize Deal and Financial Stability by TipRanks Mar 12 9:51am ET Oracle, Dollar General upgraded: Wall Street’s top analyst calls by TipRanks Mar 12 4:44am ET NGM downgraded to Market Perform from Outperform at Raymond James by TipRanks Mar 12 4:36am ET Raymond James downgrades NGM Biopharmaceuticals (NGM) to a Hold by TipRanks Mar 11 4:22pm ET NGM Biopharmaceuticals reports Q4 EPS (33c), consensus (39c) by TipRanks Feb 28 7:46am ET Downgrade to Hold: Assessing NGM Biopharmaceuticals Post-Merger Uncertainties and Pipeline Prospects by TipRanks Feb 27 6:00pm ET NGM Biopharmaceuticals downgraded to Market Perform from Outperform at TD Cowen by TipRanks Feb 27 8:49am ET NGM Biopharmaceuticals downgraded to Neutral from Buy at Citi by TipRanks Feb 26 5:23pm ET NGM Biopharmaceuticals Acquisition by Atlas Neon Parent by TipRanks Feb 26 9:50am ET NGM Biopharmaceuticals trading resumes by TipRanks Feb 26 9:07am ET NGM to be acquired by affiliates of The Column Group for $1.55 per share by TipRanks Feb 26 8:50am ET NGM Biopharmaceuticals trading halted, news pending by TipRanks Jan 31 12:45pm ET Buy Rating for NGM Biopharmaceuticals Amid Promising Drug Trials and Strategic Corporate Developments by TipRanks Jan 23 3:01am ET NGM Biopharmaceuticals Regains Nasdaq Compliance Status by TipRanks Jan 09 8:14am ET NGM announces new data from NGM707 trial, outlines strategies for candidates by TipRanks

No recent press releases are available for NGM

NGM Financials

1-year income & revenue

Key terms

NGM Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

NGM Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

NEW YORK, NEW YORK - FEBRUARY 08: A New York Community Bank stands in Brooklyn on February 08, 2024 in New York City. New York Community Bancorp, a regional lender, shed about 60% of its value over the past eight days and its credit rating has been downgraded to Junk by Moody's. (Photo by Spencer Platt/Getty Images)
Spencer Platt/Getty Images
US regional banks are still under pressure. That’s likely to continue
Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days
Students at Highlands High School, work on a practice test at the ACT Boot Camp in Newport, Ky.
Patrick Reddy/The Enquirer/AP/File
Private equity finds its next bet: college admissions
In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming